Indication:Cancer- adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
NICE guidance on olaparib (Lynparza) for treating BRCA mutation?positive, advanced ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults; https://www.nice.org.uk/guidance/ta598 â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. NICE TA381
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.
Full information at:http://www.nice.org.uk/guidance/ta381/resources/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemothera-82602844667845